Last update 24 May 2025

YH-42946

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
YH 42946, YH42946
Target
EGFR exon 20 x HER2 x Tyrosine kinase
Action
inhibitors, antagonists
Mechanism
EGFR exon 20 inhibitors(EGFR exon 20 Mutation inhibitors), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tyrosine kinase inhibitors
Therapeutic Areas
NeoplasmsRespiratory Diseases
Active Indication
Locally Advanced Malignant Solid NeoplasmNon-Small Cell Lung CancerNeoplasms+ [2]
Inactive Indication-
Originator Organization
Yuhan Corp.
Active Organization
Yuhan Corp.Yonsei University College of Medicine
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with YH-42946
NCT06616766
/ RecruitingPhase 1/2
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion
100 Clinical Results associated with YH-42946
Login to view more data
100 Translational Medicine associated with YH-42946
Login to view more data
100 Patents (Medical) associated with YH-42946
Login to view more data
100 Deals associated with YH-42946
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Malignant Solid NeoplasmPhase 2
United States
Yuhan Corp.
02 Oct 2024
Non-Small Cell Lung CancerPhase 2
United States
Yuhan Corp.
02 Oct 2024
NeoplasmsPhase 1
South Korea
Yuhan Corp.
-
EGFR-mutated non-small Cell Lung CancerPreclinical
South Korea
Yonsei University College of Medicine
29 Apr 2025
Solid tumorPreclinical
South Korea
Yuhan Corp.
08 Mar 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free